葡萄糖皮质体受体调节器的设计和开发
Frank Buttgereit1, Christian Elling2, Florian Jakob3
1Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, and Deutsches Rheumaforschungszentrum, Berlin, Germany.
合成葡萄糖皮质类药物 (GCs) 减少炎症,但引起副作用. 新的药物称为葡萄糖皮质体受体调节剂 (GRMs) 正在开发,以向特定的基因通路,提供更安全的抗炎方法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
- 药物开发 药物开发
背景情况:
- 合成葡萄糖皮质类药物 (GCs) 是强大的抗炎药物,但与显著的不良反应 (AE) 有关.
- 最初,GCs的抗炎作用和副作用被归因于葡萄皮糖类受体 (GR) 的不同的机制:分别是转抑制和转活化.
- 新出现的证据表明,GC作用的机制更复杂,促使开发新型GR调节器 (GRM).
研究的目的:
- 审查目前对GR介导基因调节的理解.
- 讨论GCs的转抑制-转活化概况,讨论其有效性和AE.
- 突出开发新型GRM的进展,包括选择性GR激应剂和调节剂 (SEGRAM).
主要方法:
- 对GR介导的基因调节现有文献的综述.
- 对GC和GRM的转抑制-转激活配置文件的分析.
- 检查设计和开发新型GRM的技术进步.
主要成果:
- 在GR转压和交换激活之间的区别提供了一个框架,用于设计具有更好的安全配置文件的GRM.
- 新的GRM正在开发中,以选择性调节GR活动,旨在将抗炎功效与AE分开.
- 瓦莫罗龙是一种分离型类固醇GRM,在2024年获得了营销许可,验证了改变GR转抑制-转活化平衡的策略.
结论:
- 调节GR转抑制-转激活平衡是开发更安全的抗炎药物的可行策略.
- 技术创新对于下一代GRM的设计和开发至关重要.
- 对新型GRMs的作用机制的进一步研究对于优化其治疗潜力至关重要.
更多相关视频
13:22A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System
Published on: September 10, 2013
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
相关概念视频
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
